Skip to main navigation

Investor Relations

Home
Investors & Media
Contact Us
Careers

Overview
News / Events
Financial
- Annual Reports & Proxies
- Financial Results
Stock
SEC Filings
- All SEC Filings
Corporate Governance

Overview
News / Events
Financial
- Annual Reports & Proxies
- Financial Results
Stock
SEC Filings
- All SEC Filings
Corporate Governance

Press Releases

Year

Nov 22, 2024

BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering

Nov 21, 2024

BioXcel Therapeutics Announces Proposed Public Offering

Nov 14, 2024

BioXcel Therapeutics Reports Third Quarter 2024 Financial Results

Nov 12, 2024

BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer’s Dementia

Nov 08, 2024

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

Oct 29, 2024

BioXcel Therapeutics to Present at ThinkEquity Conference

Oct 15, 2024

BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder

Sep 19, 2024

BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation

Sep 05, 2024

BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Aug 07, 2024

BioXcel Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 30

Site - Investor Tools

Print Page

Tear Sheet

Email Alerts

RSS Feeds

Contacts

Search

About Us
Our Products
Our Pipeline
Our Science
Patients & Advocacy

Home
Investors & Media
Contact Us
Careers

Copyright © 2024 BioXcel Therapeutics, Inc. All Rights Reserved.

Privacy Policy
Disclaimer
Sitemap